Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Takeda pays $60mm up front for rights to AMAG's Feraheme; rights returned

Executive Summary

Takeda Pharmaceutical Co. Ltd. has licensed exclusive rights to sell AMAG Pharmaceuticals Inc.'s (anemia, cardiovascular, and oncology) intravenous Feraheme (ferumoxytol) for all indications in Europe, Canada, India, Turkey, the Commonwealth of Independent States, and Asia Pacific countries excluding China (where 3SBio already has rights), Japan, and Taiwan.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register